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Background: The receptor kinase inhibitor toceranib phosphate (Palladia) was approved for use in dogs in 2009
using a dose of 3.25 mg/kg administered every other day. Preliminary data suggests that lower doses of toeceranib
may be associated with a reduced adverse event profile while maintaining sufficient drug exposure to provide
biologic activity. The purpose of this study was to determine the Cmax of toceranib in dogs with solid tumors
receiving 2.5-2.75 mg/kg every other day and to document the adverse events associated with this dose rate.
Secondary objectives included determination of plasma VEGF concentrations in treated dogs and response to
therapy.
Results: Dogs with solid tumors were administered toceranib at an intended target dose ranging from
2.5-2.75 mg/kg every other day and plasma samples were obtained for analysis of toceranib and VEGF plasma
concentrations on days 0, 7, 14 and 30 of the study at 6 and 8 hours post drug administration. Additionally, plasma
samples were obtained at 0, 1, 2, 6, 8, and 12 hours from dogs on day 30 for confirmation of Cmax. Response to
therapy was assessed using standard RECIST criteria and adverse events were characterized using the VCOG-CTCAE.
Toceranib administered at doses between 2.4-2.9 mg/kg every other day resulted in an average 6–8 hr plasma
concentration ranging from 100–120 ng/ml, well above the 40 ng/ml concentration associated with target inhibition.
Plasma VEGF concentrations increased significantly over the 30 day treatment period indicating that VEGFR2 inhibition
was likely achieved in the majority of dogs. The lower doses of toceranib used in this study were associated with a
substantially reduced adverse event profile compared to the established label dose of 3.25 mg/kg EOD.
Conclusions: Doses of toceranib ranging from 2.4-2.9 mg/kg every other day provide drug exposure considered
sufficient for target inhibition while resulting in an adverse event profile substantially reduced from that associated with
the label dose of toceranib. This lower dose range of toceranib should be considered for future use in dogs with
cancer.
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Toceranib phosphate (Palladia) is the first FDA approved
receptor tyrosine kinase inhibitor for the treatment of
cancer in dogs [1]. Toceranib acts by blocking the func-
tion of several receptors on the surface of tumor cells, as
well as on the surface of new blood vessels including
vascular endothelial growth factor receptor 2 (VEGFR2),
platelet derived growth factor receptor (PDGFR), and
stem cell factor receptor (KIT), permitting it to have
effects on both the tumor as well as the tumor micro-
environment (vasculature, etc.) [1-5]. While toceranib
was approved based on its demonstrated activity against
canine mast cell tumors (MCT), activity against various
other tumor types has been documented including sev-
eral types of carcinomas [1,3,6].
The label dose for toceranib (3.25 mg/kg given every
other day, EOD) was determined in the initial Phase I
clinical trial that established the maximum tolerated dose
(MTD) [3]. Adverse events (AEs) associated with this regi-
men included loss of appetite, lethargy, diarrhea, vomiting,
weight loss, neutropenia, and lameness [1,3]. Furthermore,
during the pivotal clinical field study of toceranib in dogs
with MCT using the 3.25 mg/kg EOD dosing regimen, ap-
proximately 20% of dogs had a dose reduction and 50%
needed a drug holiday due to AEs [1].
Based on work performed in laboratory dogs as well as
pharmacokinetic sampling from dogs in the Phase I
study [3,7,8], 3.25 mg/kg of toceranib given EOD pro-
vides sustained plasma drug concentrations at or above
40 ng/ml, the presumed necessary threshold for receptor
inhibition in vivo as established in rodent studies [4].
Furthermore, in a pharmacodynamic study performed in
dogs with MCT, a dose of 3.25 mg/kg of toceranib was
found to produce plasma concentrations of drug at
8 hours post administration ranging from 30–180 ng/ml
[5]. In this study, intratumoral target modulation as
evidenced by downregulation of KIT and/or extracellular
signal-regulated kinase (ERK) phosphorylation was dem-
onstrated at toceranib plasma concentrations as low as
30 ng/ml at 8 hours post drug administration.
Clinical evidence exists that biologic activity occurs
when doses below the MTD of toceranib are used in dogs
with a variety of tumors. For example, in the Phase I study,
of 16 dogs treated with toceranib at 2.5 mg/kg EOD, 6
(37.5%) had an objective response to therapy (4 complete
responses, CR and 2 partial responses, PR) with an add-
itional 5 dogs experiencing stable disease (SD) [3]. This
compared favorably to 20 dogs treated at 3.25 mg/kg EOD
in which 8 had an objective response to therapy (2 CR, 6
PR) with an additional 4 dogs experiencing SD. These data
provided preliminary evidence that lower doses of
toceranib may provide sufficient drug exposure to elicit
anti-tumor activity, which could then result in fewer AEs
permitting more continuous drug administration.Following its approval, toceranib was used off label in
a variety of tumor types. A retrospective study of this
use found evidence of biologic activity in anal gland anal
sac adenocarcinomas (AGASACA), thyroid carcinomas,
head and neck carcinomas, and nasal tumors [6]. The
objective response rates in these tumor types varied from
25-75%, with the clinical benefit rate (CR + PR + SD) ex-
ceeding 80%. The median dose of toceranib used in these
dogs was 2.8 mg/kg and over half the dogs were treated
on a Monday/Wednesday/Friday (MWF) dosing regimen
instead of EOD [6]. Interestingly, while the incidence of
diarrhea was comparable to that reported in the clinical
field study of toceranib in MCTs [1], the rates of anorexia,
vomiting, lethargy, and neutropenia were substantially
lower. Together, these data provide evidence that lower
doses of toceranib may be sufficient for target inhibition
while reducing the AE profile.
Although pharmacokinetic analyses have been performed
in both healthy dogs and dogs with cancer as part of the
Phase I study and in a small number dogs in the MCT piv-
otal field study [3,7], there has been no coordinated study
of toceranib plasma concentrations when intentionally
given at lower than the label dose. Therefore, the purpose
of this study was to assess the presumed maximum con-
centration of drug (Cmax) in dogs with cancer receiving an
intended dose of 2.5-2.75 mg/kg of toceranib EOD and to
evaluate changes in plasma VEGF concentrations during
the course of treatment.
Methods
Eligibility
This clinical trial was approved by the Clinical Research
and Advising Committee at the College of Veterinary
Medicine and Institutional Animal Care and Use Com-
mittee at Ohio State University. Dogs with a sarcoma,
carcinoma, melanoma or other solid tumor that had ei-
ther failed standard therapy or for which the owner de-
clined standard therapy were eligible for enrollment into
this study. Tumor types excluded from this study were
MCT, hemangiosarcoma, histiocytic sarcoma and lymph-
oma. Additional eligibility criteria included age of at least
1 year, an estimated life expectancy of at least 90 days, ad-
equate organ function as indicated by standard laboratory
tests, at least 2 weeks since prior investigational therapy,
chemotherapy, radiation therapy, or surgery, and no evi-
dence of any serious systemic disorder (e.g., cardiac dis-
ease) considered incompatible with the study.
Drug product and concomitant medication
Toceranib phosphate was provided by Pfizer Animal Health
(now Zoetis) in 10 mg, 15 mg, and 50 mg size tablets. Con-
comitant medications considered acceptable for use to pre-
vent and/or treat drug related AEs included famotidine,
omeprazole, metronidazole, loperamide, metoclopramide,
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and prednisone.
Study design
A total of 40 dogs were enrolled in this study, with dogs ini-
tially assigned to toceranib at 2.5 mg/kg or 2.75 mg/kg
EOD. All dogs were placed on famotidine at 0.5-1 mg/kg
once per day at study initiation and owners were instructed
to administer the toceranib in the morning with food. Phys-
ical examination, routine bloodwork (CBC, biochemistry
profile) and blood sampling for assessment of toceranib
and VEGF plasma concentrations was performed pretreat-
ment and on days 0, 7, 14 and 30 of treatment. On days 0,
7, and 14, blood was collected at 6 and 8 hours post drug
administration to coincide with the predicted toceranib
Cmax based on previous studies that had established the
time of maximum drug concentration (Tmax) to be 5.3-
9.3 hours [7,8]. On day 30, blood sampling was performed
at 0, 1, 2, 6, 8, and 12 hours post drug administration to
confirm either 6 or 8 hours as the true Cmax. Owners of
dogs that experienced CR, PR, or SD at study day 30 were
offered the option of continuing toceranib administration
for an additional 6 months (provided at no cost), although
patient data was not officially captured beyond day 30.
Assessment of adverse events
Dogs were evaluated for AEs on days 0, 7, 14, and 30 of
study, as well as at interim time points as needed. AEs
were defined and graded according to the published
VCOG-CTCAE criteria [9]. Disease progression or signs
and symptoms definitely related to disease were not con-
sidered AEs.
Tumor response assessment
Tumor assessments were performed on days 0, 7, 14 and
30 of study. Tumor assessment was performed using
caliper measurement with digital photography documen-
tation, thoracic radiography, ultrasonography, or spiral
computerized tomography (CT) as indicated. Determin-
ation of antitumor efficacy was based on objective tumor
assessments made according to the RECIST v.1.1 guide-
lines using unidimensional measurements [10]. Response
to therapy was defined as complete response (CR, reso-
lution of all target and non-target lesions, no new le-
sions), partial response (PR, at least 30% decrease in the
longest diameter of target lesions, no progression of
non-target lesions, and no new lesions), stable disease
(SD, decrease in target lesions of less than 30% or in-
crease of target lesions less than 20%, no progression of
non-target lesions, and no new lesions) or progressive
disease (PD, greater than 20% increase in target lesions,
progression of non-target, new lesions). Dogs were de-
fined as experiencing clinical benefit if they had CR,
PR, or SD.Blood collection and processing
Blood was collected into EDTA tubes and centrifuged at
3000 × g for 10 minutes. Plasma was then collected and
split evenly into two portions in cryovials, then stored
at −80°C until analysis was performed for toceranib
and VEGF concentrations.Analysis of toceranib plasma concentrations
Toceranib was quantitated in plasma samples using the
method previously described [7,8]. Briefly, 50 μL ali-
quots of plasma were fortified with an internal standard
(IS), a deuterated toceranib analog. Toceranib and the
IS were extracted from the plasma by protein precipita-
tion using acetonitrile. The analyte and IS are light sen-
sitive and undergo photoisomerization when exposed to
light. Therefore, the 96-well plates were protected from
light by wrapping the bottom and sides with foil and
securing with adhesive tape. Calibration standards (1 to
1000 ng/mL) and quality control (QC) samples were
prepared with separate weighing of toceranib reference
material (Pfizer, Kalamazoo, MI, 98.1% purity). Standard
and QC solutions were prepared by serially diluting a
stock solution (100 μg/mL in methanol) into control
canine plasma so that no standard or QC sample
contained more that 1% methanol. Study samples were
analyzed as single replicates.
The prepared samples were injected onto a Zorbax
StableBond CN column and elution of toceranib and the
IS accomplished with an acetonitrile:15 mM ammonium
formate solution (pH 3.25) 30/70 v/v mobile phase with
a 80/20 v/v rinse for 2.3 minutes at 5 minutes after each
injection. Detection was accomplished using MS/MS using
a Sciex 4000 triple-quadrupole mass spectrometer with
Turboionspray ionization source (MDS Sciex, Toronto,
Canada). Transition ions of m/z 397.2→ 283.2 for
toceranib and 401.3→ 283.2 for the IS were used. The
standard curves were generated using peak area ratios
of toceranib to the IS and a 1/concentration2 weighted
quadratic regression. Toceranib concentrations were
determined by interpolation over the quantitation range
of 1.00 ng/mL to 1000 ng/mL.VEGF plasma concentrations
A solid phase sandwich ELISA was used to measure
plasma concentrations of VEGF. The manufacturer’s
protocol for Canine VEGF Quantikine ELISA kit (R&D
Systems) was followed using 200 μl of undiluted plasma
and 100 μl of standard. The standard was serially diluted
to create a range of 4.88 pg/ml to 1250 pg/ml. All stan-
dards and samples were performed in duplicate and the
absorbance reading at 540 nM was subtracted from the
absorbance reading at 450 nM.













Soft tissue sarcoma 7
Thyroid carcinoma 7
Anal sac adenocarcinoma 7
Nasal carcinoma 5
Squamous cell carcinoma 4
OSA (lung metastasis) 3
Primary pulmonary carcinoma 3
Billiary carcinoma 1
Poorly differentiated carcinoma (neck and jaw) 1
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VEGF concentrations were analyzed in terms of percent
change from baseline. Repeated measures ANOVA (with
the Greenhouse-Geisser correction to account for lack
of compound-symmetry) was used to determine if per-
cent change in VEGF differed between 0, 7, 14, and
30 days. Percent change in VEGF (dependent variable)
was also related to Cmax and Tmax, (independent vari-
ables) using separate linear mixed models containing
animal-specific intercepts and slopes and a power correl-
ation structure for the residual errors to allow within
animal correlations to differ with proximity of measure-
ments. The Bayesian Information Criterion (BIC) was
used to select between linear, quadratic, and cubic trends
in our mixed models. Repeated Measures ANOVA was
performed using Intercooled Stata Version 11 (Stata
Corp, College Station, TX) and the linear mixed models




A total of 40 dogs were enrolled in the study between Au-
gust 2010 and December 2011. All dogs were treated and
followed at The Ohio State University Veterinary Medical
Center. Thirty-nine dogs completed the study; one patient
did not finish the study as the owner elected euthanasia.
Baseline characteristics for the 40 dogs are presented in
Table 1. Median age upon study enrollment was 9.8 years
and the median body weight was 30.5 kg. The majority of
dogs entered were mixed breed dogs. Tumor types in-
cluded soft tissue sarcoma (n = 7), AGASACA (n = 7)
thyroid carcinoma (n = 7), nasal carcinoma (n = 5), squa-
mous cell carcinoma (n = 4), primary pulmonary carcin-
oma (n = 3), metastatic osteosarcoma (n = 3), biliary
carcinoma (n = 1), poorly differentiated carcinoma in the
neck region (n = 1), salivary gland adenocarcinoma (n = 1),
and mediastinal carcinoma (n = 1). Fifteen dogs had re-
ceived prior therapy consisting of surgery, chemotherapy,
and/or radiation therapy, and 25 dogs had not received
any prior treatment.
Dosing of toceranib
Dogs were initially assigned a dose of either 2.5 mg/kg
or 2.75 mg/kg. However, given tablet size limitations, the
dose rates were not exact, and this was further
compounded by changes in body weight during the
study as well as the need for an occasional dose adjust-
ment due to AEs. Table 2 shows the actual mean doses
of toceranib for dogs enrolled in the study determined
by averaging the dose calculated over the four study
visits. These are grouped by range of dose, and the num-
ber of dogs in each dose range is provided. The number
of dogs requiring a dose modification was five for thoseinitiated at 2.5 mg/kg and three for those initiated at
2.75 mg/kg.Response to therapy
Tumors were assessed at baseline and again on days 7,
14 and 30 or at the time of suspected progression by dir-
ect measurement, thoracic radiography, abdominal ultra-
sound or CT. SD over 30 days was observed in 31/40
dogs (77.5%) and 5/40 dogs experienced PR to therapy
(12.5%) for an overall clinical benefit rate of 90%. There
were 4 dogs (10%) that developed PD during the course
of treatment. These data are summarized in Table 3.Adverse events
Drug-related AEs were limited and in most cases readily
treatable with supportive care. Using the VCOG-CTCAE
classification [9] there were 188 grade 1, 27 grade 2, 8
grade 3, and 1 grade 4 AEs (Table 4); these are described
below:
Table 2 Toceranib dosing groups
Dose range (mg/kg)
2.35-2.39 2.40-2.49 2.50-2.59 2.60-2.69 2.70-2.79 2.80-2.89
2.35 2.40 2.50 2.62 2.70 2.89
2.38 2.41 2.50 2.62 2.70
2.39 2.47 2.50 2.63 2.72












Table 4 Adverse events in toceranib treated dogs







Increase ALP 9 2 1
Increase BUN 9 1
Increase ALT 7 1 1
Lameness 6 8 1
Increase AST 5 1
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Fifteen dogs (52.5%) developed grade 1 diarrhea during
the study, 10 of which experienced more than one epi-
sode. Six dogs developed grade 2 diarrhea, and two had
grade 2 colitis. Eighteen dogs (37.5%) developed grade 1
vomiting, 5 of which experienced more than one event;
only 3 dogs experienced grade 2 vomiting. Thirteen dogs
(32.5%) developed grade 1 anorexia and 1 had grade 2
anorexia. Lethargy was encountered in 13 dogs (32.5%),
11 of which were grade 1 episodes with the remainder
grade 2 in severity. Only 3 dogs had weight loss, ranging
from 5-10% of their initial recorded body weight, con-
sistent with a grade 1 event.Table 3 Response to therapy by tumor type
Tumor type N PD SD PR
Soft tissue sarcoma 7 2 5
AGASACA 7 7
Thyroid carcinoma 7 5 2
Nasal carcinoma 5 2 3
Squamous cell carcinoma 4 2 2
Metastatic osteosarcoma (lung) 3 3
Primary pulmonary carcinoma 3 3
Billiary carcinoma 1 1
Poorly differentiated carcinoma 1 1
Salivary gland adenocarcinoma 1 1
Mediastinal carcinoma 1 1
Total 40 4 31
PD Progressive Disease SD, Stable disease PR Partial response.
Pruritus 1
Constipation 1
Constipation 188 27 8 1Hematologic
In 42.5% (20/40) of the dogs, grade 1 neutropenia was
documented after 1–3 weeks of toceranib therapy; only
1 episode of grade 2 neutropenia was documented in all
dogs. These events were not associated with infection or
fever and in most instances the neutropenia resolved
over time. In those cases where neutropenia persisted
during the course of therapy, the grade did not worsen.
Thirteen dogs experienced grade 1 anemia during the
study, 6 of which had a mild anemia of chronic disease
prior to beginning toceranib administration. Only 2 dogs
developed grade 1 thrombocytopenia.
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Increased blood urea nitrogen (BUN) without a con-
comitant increase in creatinine was noted in 9 dogs, of
which 6 had concurrent gastrointestinal upset. Transient
grade 1 elevations in alanine aminotransferase (ALT)
were noted in 7 dogs and not associated with any specific
clinical signs; these resolved spontaneously without dis-
continuation of therapy. Five dogs had mild increases in
aspartate aminotransferase (AST, grade 1) and 1 dog de-
veloped a grade 3 AST elevation at the end of the study
period. Alkaline phosphatase elevations (grade 1, n = 10,
grade 3, n = 1) were observed as well. Of note, no dogs
enrolled in this study developed clinical evidence of
hepatotoxicity.
Neuromuscular
Mild- to-moderate lameness (grade 1–2) occurred in 10
dogs; 1 dog experienced grade 3 lameness, (severe with
occasional weight bearing on the affected limb). Physical
examination in affected dogs often revealed focal muscle
pain, but no obvious joint or bone pain. The lameness
resolved in all cases with rest, pain medication (e.g.,
tramadol, carprofen, meloxicam) or a change in the
toceranib dose.
Other adverse events
Other side effects experienced by dogs enrolled in this
study included ocular discharge, coughing, epistaxis,
panting, hypertension, pancreatitis, ileus, protein losing
nephropathy, and various skin disorders. For the major-
ity of these attribution was unlikely to be associated with
toceranib; rather, the events were either a consequence
of disease and/or due to other causes (i.e., concomitant
medications, etc.). Grade 3 hypertension developed in 2
dogs; discontinuation of toceranib and initiation of enal-
april resolved the event in one dog, while the other dog’s
hypertension was believed secondary to pain associated
with the tumor and the development of pancreatitis. In
this dog, pancreatitis was diagnosed based on clinical
signs (acute vomiting, lethargy, weakness, and an ele-
vated cPLI at 470 ug/L). Although the dog was improv-
ing clinically with supportive care, the owners elected
euthanasia due to a poor prognosis associated with the
tumor (soft tissue sarcoma attached to the thoracic wall
in the axillary region). A full necropsy was performed
and although gross findings appeared consistent with
pancreatitis, this was not confirmed upon histopatho-
logic examination of the pancreas.
There were 4 patients that developed protein losing
nephropathy (PLN) without an apparent cause, one of
which had concurrent hypertension. All patients showed
an inactive sediment and absence of blood in the urine.
Three out of these 4 patients continued on toceranib
after the study and went on to receive enalapril +/−amlodipine; the proteinuria remained stable despite con-
tinued therapy.
One dog on study developed depigmentation and thin-
ning of the footpads in all 4 limbs. This was associated
with pain/hypersensitivity when walking. The toceranib
was discontinued for 1 week at which time the AE re-
solved and drug was continued at a lower dose.
Management of adverse events
The adverse events discussed above were primarily grade
1 and 2 in nature and in nearly all dogs resolved with the
addition of concomitant medications and/or temporary
discontinuation of toceranib administration. Medications
used to treat/prevent these toxicities included famotidine,
omeprazole, metoclopramide, maropitant, ondansetron,
metronidazole, loperamide, enalapril, tramadol, prednis-
one and NSAIDs (carprofen or meloxicam). In addition to
the dog that presented with pancreatitis, one other dog
required hospitalization due to vomiting and diarrhea of
one-day duration. This resolved with fluids, metoclo-
pramide, famotidine, metronidazole, and ondansetron and
toceranib administration was re-initiated without further
complication.
Analysis of toceranib plasma concentrations
A primary objective of this study was to evaluate the pre-
sumed Cmax of toceranib given at doses below that indi-
cated on the label (3.25 mg/kg) to determine whether
these doses were associated with concentrations of drug
likely to result in biologic activity. In prior studies the
Cmax was determined to be approximately 6–8 hours
post drug administration [7,8]. Additionally, a pharmaco-
dynamic study in dogs demonstrated that plasma concen-
trations of toceranib 8 hours post drug administration
ranging from 30 to 180 ng/ml were associated with target
modulation in vivo [5].
The plasma concentrations of drug at 6 and 8 hours
were measured and the highest value was used as the
presumed Cmax at days 0, 7 and 14. The plasma sam-
ples taken at day 30 over 12 hours confirmed that this
was true for 69% (28) of the dogs who had a Cmax at 6
or 8 hours. Of the 12 dogs with Cmax at 12 hours, the
reported Cmax ranged from 51% to 98% of the 12 hour
concentration: 5 were at > 90%, 8 were > 80%, 10 were >
75% of the 12 hour concentration. Figure 1 shows repre-
sentative plasma toceranib concentrations at day 30 from
4 dogs. Therefore, for all dogs the plasma concentration
reported as Cmax was the true maximum plasma concen-
tration of toceranib post administration, or a value < 25%
lower than the Cmax. These values are shown in Figure 2,
grouped by dose range. The presumed Cmax plasma con-
centration of toceranib increased gradually in most dogs
over the first 2 weeks of dosing despite the EOD regimen

































Figure 1 Toceranib plasma concentrations on day 30 of
treatment. Shown are representative plasma toceranib
concentrations from 4 dogs obtained on day 30 over 12 hours
following drug administration. In this study, 28/40 dogs had Cmax at
6 or 8 hours on day 30. Two of the dogs shown experienced Cmax
























Figure 2 Toceranib Cmax concentrations. Shown are the median Cmax
presented for each time point of collection (days 0, 7, 14, and 30) by dose
40 ng/ml concentration of toceranib predicted to be associated with effec
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sumed Cmax values of 100–200 ng/ml by day 30, well
above the 8 hour 40 ng/ml plasma concentration consid-
ered to be sufficient for target inhibition in vivo. Lastly,
there did not appear to be significant differences in drug
exposure in dogs dosed between 2.4-2.9 ng/ml by day 30
of dosing.Plasma VEGF
Plasma was collected from dogs 8 hours post dosing on
days 0, 7, 14, and 30 and analyzed by ELISA for VEGF
concentrations. As shown in Figure 3, although plasma
VEGF baseline concentrations were generally very low
in most dogs (10–40 pg/ml) they did increase signifi-
cantly over the study period (p < 0.001). Furthermore,
plasma VEGF concentrations appeared to plateau over
days 14 to 30, potentially correlating with the leveling out
of toceranib drug peak plasma concentrations. Change in
VEGF was associated with Cmax (p < 0.001), but not






concentrations of dogs treated with toceranib in this study. These are

































D1:0hr D1:8hr D7:8hr D14:8hr D30:8hr
Time of Collection
Figure 3 Change in plasma VEGF in toceranib treated dogs.
Plasma VEGF concentrations were assessed in dogs prior to
toceranib therapy then at 8 hours post dosing on days 1, 7, 14, and
30 of the study. The percent change in plasma VEGF over the
30 day study period was then assessed. Plasma VEGF concentrations
increased significantly from baseline over the 30 day study period
(p < 0.001). Furthermore, plasma VEGF concentrations appeared to
plateau over days 14 to 30. Change in VEGF was associated with
Cmax (p < 0.001) but not Tmax (p = 0.74).
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Toceranib (Palladia), a multitargeted receptor tyrosine
kinase inhibitor was approved by the FDA in 2009 for
the treatment of canine MCTs. Based on the pivotal
clinical field study the subsequent product label indi-
cated that drug should be administered at 3.25 mg/kg
EOD with guidelines for dose reduction as needed to ad-
dress AEs [1]. However, the initial Phase I clinical trial
of toceranib suggested that a dose of 2.5 mg/kg was as-
sociated with equivalent biologic activity as that achieved
with the MTD [3]. A more recent retrospective study
demonstrated significant clinical benefit when toceranib
was administered at a median of 2.8 mg/kg [6].
In the current study, dogs with solid tumors were
administerd toceranib at an intended dose of 2.5 or
2.75 mg/kg EOD and AEs, response to therapy and
plasma concentrations of toceranib and VEGF were
assessed. Pharmacokinetic analysis showed that for dogs
dosed in the 2.4-2.9 mg/kg range, there was no signifi-
cant difference among dosing groups with respect to the
6 or 8 hour drug concentrations (presumed Cmax) at
each time point tested. Dogs dosed at 2.30-2.39 mg/kg
appeared to have lower concentrations of drug at all
time points, although there were only 3 dogs in this
dose range. Median plasma concentrations of toceranib
measured at 6 or 8 hours increased over the first two
weeks of therapy for dogs dosed between 2.4-2.9 mg/kg,
before leveling off at 100–120 ng/ml. These results dif-
fer from those obtained in healthy beagle dogs, where
toceranib Cmax was proportional to doses ranging from2.0 to 6.0 mg/kg [7]. The reason for this is not clear,
however it is possible that some differences in drug
absorption may occur among dogs with a variety of co-
morbidities (such as cancer) compared to that found in
laboratory healthy research dogs. Given the studies in
mouse models and dogs with MCT demonstrating tar-
get inhibition at toceranib plasma concentrations at or
above 40 ng/ml [2,4] dosing of toceranib at 2.4-2.9 mg/
kg results in plasma concentrations of drug likely to ef-
fectively inhibit target receptor tyrosine kinases in vivo.
A substantial motivation for assessing whether lower
doses of toceranib can be used in dogs with cancer arises
from the observed AE profile of the drug. Known AEs
include those involving the gastrointestinal tract (anorexia,
diarrhea, vomiting), hematologic system (neutropenia,
anemia) and neuromuscular system (lameness, weakness),
with hepatopathy, proteinuria, hypertension and pancrea-
titis less frequently reported [1,3]. In the retrospective
study of toceranib in solid tumors, while the AEs reported
were similar to those established in the pivotal field study,
the rates of anorexia, vomiting, lethargy and neutropenia
were substantially lower [6].
While the ability to compare toxicities among the pub-
lished clinical trials evaluating toceranib in dogs with
cancer is limited due to variability in dose rates and
dosing schedules used, it does appear that the use of
lower doses of drug are associated with significantly fewer
grade 3 and 4 AEs. Similar to prior studies, the main AEs
observed were GI, hematologic (neutropenia) and muscu-
loskeletal in nature and the majority (86%) were either
grade 1 or grade 2 in severity (74% and 12%, respectively).
However, the number of grade 3 and 4 adverse events was
very low, and 3 of these 9 events (pancreatitis, hyperten-
sion and ileus) occurred in the dog that experienced an
episode initially characterized as pancreatitis that was not
confirmed on histopathology following necropsy. Three
additional dogs experienced grade 3 and 4 AEs and only
the grade 3 lameness was associated with clinical effects.
Importantly, no grade 3 or 4 GI adverse events were
documented; this is in contrast to the pivotal field study
using 3.25 mg/kg dosing in which grade 3 or 4 diarrhea,
vomiting and anorexia occurred in 6.9%, 9.2% and 6.2% of
treated dogs, respectively [1].
In the current study we documented AEs not previ-
ously formally noted with toceranib administration, al-
though these have been reported anecdotally including
PLN, hypertension and a presumed hand-foot like syn-
drome. Hypertension and PLN are AEs known to occur
with the administration of anti-angiogenic agents to hu-
man cancer patients. In human patients with renal cell
carcinoma (RCC) receiving the closely related tyrosine
kinase inhibitor sunitinib, 24% developed hypertension
and 8% of these were classified as grade 3 in nature [11].
In the current study, only 3 dogs developed hypertension,
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may have been underreported as blood pressure was mea-
sured only in animals showing signs consistent with sys-
temic hypertension or illness. While the exact mechanism
of hypertension associated with toceranib is not clear, it
may be directly related to inhibition of VEGF signaling
pathways [12]. Additionally, anti-angiogenic drugs used in
human patients have been shown to induce increased con-
centrations of endothelin-1, and this may contribute to
the observed hypertension [13-15].
The development of PLN in dogs treated with toceranib
has not been described in previous clinical trials, although
in these studies routine urinalysis was not performed at
study visits. In the current study, urinalysis was similarly
only performed at baseline and not repeated unless clin-
ical signs dictated the need to do so. As such, the actual
incidence of PLN may have been underreported. In hu-
man cancer patients that receive sunitinb the incidence of
PLN has been reported to be approximately 2.5% [16-19].
The mechanisms through which VEGF/VEGFR signaling
inhibitors cause proteinuria are not well understood, but
several have been proposed including the loss of healthy,
fenestrated glomerular capillaries which seems to be a dir-
ect consequence of blocking VEGFR signaling and pos-
sibly disruption of podocyte integrity [16-19].
In this clinical trial, only 8 dogs (20%) had their dose
changed throughout the study period (drug holiday and/
or dose reduction) compared to 48.3% in the pivotal
field study which used the label dose of 3.25 mg/kg [1].
Although limitations exist when comparing data from
different studies, it does appear that the reduced AE
profile associated with lower doses of toceranib results
in fewer changes to the treatment regimen than those
that occur using the MTD.
While tumor response was not one of the main objec-
tives of this study, clinical benefit was observed in 36/40
(90%) of the patients, with 12.5% experiencing PR and
77.5% experiencing SD; only 10% of dogs developed PD.
Furthermore, 35 of the 40 dogs remained on toceranib
for an average of 16.7 weeks after day 30. During this time,
one dog with a thyroid carcinoma transitioned from SD to
a PR and 3 dogs transitioned to CR (two SCC and one sal-
ivary gland adenocarcinoma). These data support the no-
tion that administration of toceranib at doses ranging
from 2.4-2.9 mg/kg is associated with meaningful clinical
benefit in dogs with cancer.
In human patients administered sunitinib, concentra-
tions of circulating endothelial precursors and plasma
VEGF have been shown to increase over time during
treatment [20]. Unlike toceranib, sunitinib is generally
administered daily for 28 days, followed by a rest period
of 14 days, and these concentrations return to baseline
during the rest period. It has been hypothesized that
continual inhibition of the VEGF/VEGFR signaling axisresults in a feedback mechanism promoting an enhanced
angiogenic response [21]. The increase in VEGF during
treatment with sunitinib or other VEGF/VEGFR inhibi-
tors is generally believed to be a surrogate biomarker of
pathway inhibition. In the current study we found that
plasma VEGF concentrations increased over time despite
using toceranib at the lower dose and giving drug on an
EOD basis. This finding further supports the premise
that lower doses of toceranib are associated with bio-
logically relevant plasma concentrations of drug.Conclusions
In summary, toceranib administration at doses between
2.4-2.9 mg/kg EOD results in plasma drug concentra-
tions associated with expected receptor kinase inhib-
ition. This is supported by the fact that 90% of treated
dogs experienced clinical benefit over the 30 day treat-
ment period and 35/40 dogs continued on toceranib
following study conclusion. Importantly, AEs associated
with toceranib administration at the lower doses were
well tolerated with no grade 3 or 4 GI events, compared
to those reported with dosing at the MTD of 3.25 mg/
kg. Together, these data support the use of toceranib at
doses ranging from 2.4-2.9 mg/kg.
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